Mesoblast has gained US Food and Drug Administration (FDA) approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil (reme...
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over. Th...
After its market withdrawal in 2022, GSK’s multiple myeloma drug Blenrep (belantamab mafodotin) is poised to re-enter the treat...
Disc Medicine has announced a US Food and Drug Administration (FDA) agreement on the regulatory path for its investigational drug...